top of page
Facilitate and assist R&D activity
Assist corporate development for start-up companies
News
Apr, 2024
Mar 2024
Dec 2023
Dec 2023
Jan 2023
Dec 2022
Oct 2022
Jun, 2022
Dec, 2021
Apr, 2021
NeoVascularX, Inc. licensed exclusive worldwide rights to AMD101 topical ophthalmic products from AMD Therapeutics LLC and its co-development partners.
Presenting AMD101 topical ophthalmic products at 4ᵗʰ Wet AMD & Diabetic Eye Disease Drug Development Summit in Boston (3/19/24-3/21/24).
US patent for AMD101 topical ophthalmic products issued.
A new PCT patent application for AMD101 topical ophthalmic products published.
Presentation at Biotech Showcase in San Francisco (1/11/23, 10:30AM)
Japan patent for SCR101 topical skin products issued.
Head office in Palo Alto, California (San Francisco Bay Area)
A new PCT patent application for AMD101 topical ophthalmic products published
Re-domiciled California LLC registration to Delaware
Japan patent for AMD101 topical ophthalmic products issued.
Dec 2020
Jul, 2020
Dec, 2019
Feb, 2019
Jun, 2015
Extensive pre-clinical activities to develop AMD101 topical ophthalmic products
US patent for SCR101 topical skin products issued.
Participated in an annual conference of Japanese Retina and Vitreous Society.
Presented AMD Therapeutics at RINK Festival in Kawasaki-City, Japan.
Registered AMD Therapeutics LLC in California
bottom of page